Oxaliplatin-induced immune mediated thrombocytopenia.
Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.
Beg
Muhammad S
MS
Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Komrokji
Rami S
RS
Ahmed
Kashif
K
Safa
Malek M
MM
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001792:Blood Platelets / Q000378:metabolism; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000191:economics; D008562:Membrane Glycoproteins / Q000097:blood / Q000378:metabolism; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D000077150:Oxaliplatin; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology*
D000970:Antineoplastic Agents; D008562:Membrane Glycoproteins; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil